SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (IMMUN

显示全部楼层 · 发表于 2025-3-25 04:59:38

Submitted on: 02 November 2022. Revised on: 04 January 2023. Accepted on: 17 February 2023. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets

显示全部楼层 · 发表于 2025-3-25 08:15:39

显示全部楼层 · 发表于 2025-3-25 11:54:40

显示全部楼层 · 发表于 2025-3-25 19:52:21

Submitted on: 17 February 2009. Revised on: 03 May 2009. Accepted on: 16 June 2009. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets

显示全部楼层 · 发表于 2025-3-25 21:43:10

Submitted on: 22 December 2010. Revised on: 08 February 2011. Accepted on: 12 March 2011. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets

显示全部楼层 · 发表于 2025-3-26 01:38:29

显示全部楼层 · 发表于 2025-3-26 05:23:04

显示全部楼层 · 发表于 2025-3-26 08:48:05

显示全部楼层 · 发表于 2025-3-26 15:51:27

Submitted on: 02 November 2022. Revised on: 24 February 2023. Accepted on: 19 April 2023. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets

显示全部楼层 · 发表于 2025-3-26 19:28:42

Submitted on: 22 March 2019. Revised on: 16 July 2019. Accepted on: 08 August 2019. ___________________Endocrine Metabolic & Immune Disorders-Drug Targets

		自动登录	找回密码
密码			To register

关于派博传思			派博传思旗下网站			友情链接
派博传思介绍	公司地理位置	论文服务流程	影响因子官网	SITEMAP	大讲堂	北京大学	Oxford Uni.	Harvard Uni.
发展历史沿革	期刊点评	投稿经验总结	SCIENCEGARD	IMPACTFACTOR	派博系数	清华大学	Yale Uni.	Stanford Uni.
\|Archiver\|手机版\|小黑屋\| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-4-27 11:21
Copyright © 2001-2015 派博传思京公网安备110108008328 版权所有 All rights reserved

SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (IMMUN

浏览过的版块